Observational studyCancer medicine2017
Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.
Observational study in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Risk factors for catheter-related thrombosis in cancer patients: a systematic review.Frontiers in cardiovascular medicine · 2026Review
- Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions.Frontiers in oncology · 2026Article
- A Comprehensive Review of Catheter-Related Thrombosis.Journal of clinical medicine · 2024Review
- Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study.BMC cancer · 2024Article
- Do we need to treat asymptomatic catheter-related thrombosis?Research and practice in thrombosis and haemostasis · 2024Article
- Retrospective analysis: 5509 cases of "totally implantable venous access port systems implantation (TIVAPS) depth" assisted by digital radiography.Langenbeck's archives of surgery · 2022Article
- Risk factors associated with venous thromboembolism in breast cancer: a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Catheter-related thrombosis (CRT) in patients with solid tumors: a narrative review and clinical guidance for daily care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner.Current oncology (Toronto, Ont.) · 2022Review
- Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter-related thrombosis.Research and practice in thrombosis and haemostasis · 2022Article
- A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Review
- The role of hemostatic markers as venous stenosis or occlusion predictors following first transvenous cardiac device implantation.Cardiology journal · 2021Article
- Intraoperative ipsilateral subclavian port catheter implantation in resectable breast cancer patients: A novel, safe, and convenient clinical practice.Cancer medicine · 2020Article
- Incidence of and risk factors for totally implantable vascular access device complications in patients with gastric cancer: A retrospective analysis.Molecular and clinical oncology · 2019Article
- Predictors of venous stenosis or occlusion following first transvenous cardiac device implantation: Prospective observational study.The journal of vascular access · 2019Observational
- Diagnosis and Treatment of Arterial Occlusion after Knee Arthroplasty: The Sooner, the Better.Orthopaedic surgery · 2019Review
- Review
- Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.Cancer medicine · 2017Observational
- Venous Thromboembolism in Women with Breast and Gynaecological Cancers: What Do We Know and What Should We Do?Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous epidemiologic studies investigating central venous catheter (CVC)-related venous thromboembolism (CRT) were conducted in heterogenous cancer populations and data in breast cancer (BC) remain limited. To investigate the Doppler ultrasound (DUS)-CRT incidence, risk factors and outcomes in BC, we designed a prospective, multicenter cohort of nonmetastatic invasive BC patients undergoing insertion of a CVC for chemotherapy. All patients underwent double-blind DUS before, 7, 30, and 90 days after CVC insertion and a 6 months clinical follow-up. Symptomatic DUS-CRT were treated by anticoagulants. D-Dimers, thrombin generation, and platelet-derived microparticles were measured before and 2 days after CVC placement. In DUS-CRT patients, a nested case-control study analyzed the role of thrombophilia. Among 524 patients, the DUS-CRT (14 symptomatic, 46 asymptomatic) cumulative probability was 9.6% at 3 months and 11.5% at 6 months (overall incidence rate: 2.18/100 patient-months). Ten/14 symptomatic DUS-CRT were detected on double-blind DUS before the clinical symptoms, and 3/14 had a simultaneous pulmonary embolism. No clinical thrombotic event subsequently occurred in untreated asymptomatic DUS-CRT. Age >50 years (OR, 1.80; 95% CI, 1.01-3.22), BMI >30 kg/m² (OR, 2.64; 95% CI, 1.46-4.76) and comorbidities (OR, 2.05; 95% CI, 1.18-3.56) were associated with DUS-CRT. No biomarkers was found to predict DUS-CRT. In multivariate analysis, BMI >30 kg/m² (OR, 2.66; 95%CI, 1.46-4.84) and lobular carcinoma histology (OR, 2.56; 95%CI, 1.32-4.96) remained the only significant DUS-CRT risk factors. Thrombophilia did not account for DUS-CRT. Only clinical parameters identified high risk DUS-CRT patients who may be considered for thromboprophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.